Top

Published in:

01-09-2010 | Original Article

Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study

Published in: Osteoporosis International | Issue 9/2010

Abstract

Summary

This prospective study, in the very early phase after initiation of glucocorticoid (GC) treatment, showed that alendronate was effective in suppressing accelerated bone resorption and subsequent decrease in bone mineral density (BMD) at the lumbar spine of patients with high-dose GC treatment.

Introduction

How bisphosphonates affect bone metabolism and BMD of patients with high-dose GC in the early phase, especially within 1 month is unclear.

Methods

We examined the prospective effects of daily 5 mg alendronate on bone metabolism and BMD in 20 patients with high-dose GC (at least 40 mg prednisolone/day) and compared them to 34 high-dose GC-treated patients without alendronate.

Results

Serum levels of calcium decreased at day 28 in the alendronate group. Urinary calcium excretion significantly increased after day 7 in both groups. The increase in serum parathyroid hormone (PTH) level at day 7 in the control group was not observed in the alendronate group, but PTH levels increased at day 28 and month 3 in the alendronate group. As for the bone turnover markers, the serum osteocalcin level decreased in both alendronate and control groups, but serum bone-type alkaline phosphatase levels did not show significant changes. Although the urinary type I collagen cross-linked N-telopeptide (NTX) level showed significant increases on days 7 and 28 in the control group; such early increases in urinary NTX were not observed in the alendronate group. Thereafter, the urinary NTX levels fell slowly in the alendronate group significantly. BMD at the lumbar spine significantly decreased from month 1 in the control group, whereas in the alendronate group, BMD at the lumbar spine maintained almost the same level at all time points observed.

Conclusion

Alendronate was effective in suppressing bone resorption and subsequent BMD decrease at the lumbar spine in patients with high-dose GC treatment.

Sambrook P, Birmingham J, Kempler S et al (1990) Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 5:1211–1216CrossRefPubMed

Van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000CrossRefPubMed

Van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMed

Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229CrossRefPubMed

Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323–328CrossRefPubMed

Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899CrossRefPubMed

Kaji H, Sugimoto T, Kanatani M et al (1997) Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res 12:734–741CrossRefPubMed

Iu MF, Kaji H, Sowa H et al (2005) Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol 185:131–138CrossRefPubMed

Mazziotti G, Angeli A, Bilezikian JP et al (2006) Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17:144–149CrossRefPubMed

10.

Canalis E, Mazziotti G, Giustina A et al (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328CrossRefPubMed

11.

Kaji H, Yamauchi M, Chihara K et al (2008) Glucocorticoid excess affects cortical bone geometry in premenopausal, but not postmenopausal women. Calcif Tissue Int 82:182–190CrossRefPubMed

12.

Kaji H, Yamauchi M, Chihara K et al (2008) Relationship between endogenous parathyroid hormone and bone metabolism/geometry in female patients treated with glucocorticoid. Horm Metab Res 40:60–65CrossRefPubMed

13.

Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443CrossRefPubMed

14.

Cranney A, Wells G, Willan A et al (2002) Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516CrossRefPubMed

15.

Cranney A, Tugwell P, Adachi J et al (2002) Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523CrossRefPubMed

16.

Kaji H, Hisa I, Inoue Y et al (2009) Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. J Bone Miner Metab 27:76–82CrossRefPubMed

17.

Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082CrossRefPubMed

18.

Hochberg MC, Thompson DE, Black DM et al (2005) Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 20:971–976CrossRefPubMed

19.

Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299CrossRefPubMed

20.

Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial. Arthr Rheumat 44:202–211CrossRef

21.

Amin S, Lavalley MP, Simms RW et al (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512–1526CrossRefPubMed

22.

Parker CR, Blackwell PJ, Fairbairn KJ et al (2002) Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 87:4482–4489CrossRefPubMed

23.

Nawata H, Soen S, Takayanagi R et al (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research. J Bone Miner Metab 23:105–109CrossRefPubMed

24.

Shimon I, Eshed V, Doolman R et al (2005) Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int 16:1591–1596CrossRefPubMed

25.

de Nijs RNJ, Jacobs JWG, Lems WF et al (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675–684CrossRefPubMed

26.

Mok CC, Tong KH, To CH et al (2008) Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int 19:357–364CrossRefPubMed

27.

Okada Y, Nawata M, Nakayamada S et al (2008) Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 35:2249–2254CrossRefPubMed

28.

Gomez B, Ardakani S, Ju J et al (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560–1566PubMed

29.

Blackburn GF, Shah HP, Kenten JH et al (1991) Electrochemiluminescence detection for development of immunoassay and DNA probe assays for clinical diagnosis. Clin Chem 37:1534–1539PubMed

30.

Woitage HW, Pecherstorfer M, Li Y et al (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792–801CrossRef

31.

Kuroki Y, Kaji H, Kawano S et al (2008) Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 26:271–278CrossRefPubMed

32.

Haugeberg G, Griffiths B, Sokoll KB et al (2004) Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann Rheum Dis 63:940–944CrossRefPubMed

33.

Jacobs JW, de Nijs RN, Lems WF et al (2007) Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of changes in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol 34:1051–1057PubMed

Title: Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study
Publication date: 01-09-2010
Published in: Osteoporosis International / Issue 9/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-1110-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2010

Osteocyte: the unrecognized side of bone tissue

Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women: The Japanese Population-based Osteoporosis (JPOS) Cohort Study

Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism

Comparison of the effects of two resistance training regimens on muscular and bone responses in premenopausal women

Automated 3D trabecular bone structure analysis of the proximal femur—prediction of biomechanical strength by CT and DXA

Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility